Future studies therefore need to investigate possible anti-angiogenic effects of PSMA-targeted radionuclide therapy in tumors with PSMA-expressing neovessels especially in metastatic dedifferentiated thyroid cancer, where radioactive iodine therapy becomes ineffective to control disease. Here, FOLH1 is linked to thyroid cancer.